PPT-Access to Controlled Medicines

Willem Scholten PharmD MPA Team Leader Access to Controlled Medicines World Health Organization Geneva Switzerland TECHNICAL BRIEFING SEMINAR Geneva 29 October 2 November 2012 Overview. Concept and Process. IPC Meeting. June 6, 2014 – WHO Geneva. Nicola Magrini – WHO, EMP. Essential Medicines. Guiding principle:. . A limited range of carefully selected essential medicines leads to better health care, better medicines management, and lower costs. Zambia Civil Society Consultation Meeting. 1. st. October 2013 . Daniel S. . Libati. , LLB (UNZA) . CSO Consultant. Basis of CSO work?. When one speaks of civil society and its work with regards to engaging government, the first question that has to be settled before such engagement takes place is with regards to the ‘BASIS’ of such engagement.. for asthma. WHO . Technical. Briefing . Seminar. on Essential . Medicines. & Health . Products. , Nov. 2013. Christophe Perrin, . Pharmacist. , MPH – IUATLD (The Union). Asthma. . - Global . Cochin University of Science & Technology . Sakthivel. . Selvaraj. Public Health Foundation of India . New . Delhi . (shakti@phfi.org). Access to Medicines in India . Key Barriers to . Access to Medicines . Willem Scholten, PharmD, MPA. Team Leader, Access to Controlled Medicines,. World Health Organization, Geneva, Switzerland. TECHNICAL BRIEFING SEMINAR . Geneva, 29 October – 2 November 2012. Overview. Gilles Forte. Policy. , Access and Use Team. Department for Essential . Medicines and Health Products. World Health Assembly Resolution 67.22 . Access . to essential medicines. Recognize . the importance of effective national medicines policies, and their . Gilles . Forte. Coordinator, Policy, Access and Use Team. Essential . Medicines . and . Health Products. . WHO . mandate . within the . International . Drug Control Conventions. 1961 . Single Convention on Narcotic Drugs (Article 3). Dr Jane Robertson. Policy, Access and Use Team, EMP. 4 November 2014. Appropriate use of medicines. Relies on a number of elements. Availability. , . affordability, and use in practice of effective medicines. WHO EMP and NVI Departments. Access to NCD essential medicines . on the global agenda. Access to chronic disease medicines is required for the fulfilment of MDG8. Governments, in collaboration with the private sector, should give greater priority to treating chronic diseases and improving the accessibility of medicines to treat them (MDG Report 2009). sustainably and equitably financed. Summary Discussion…1. What information needed to estimate cost program of medicines benefits. MBM . Ned to estimate the total economic cost of setting up a MBM program. for asthma. WHO . Technical. Briefing . Seminar. on Essential . Medicines. & Health . Products. , Nov. 2013. Christophe Perrin, . Pharmacist. , MPH – IUATLD (The Union). Asthma. . - Global . Draft concept for a new World Bank-led multi-stakeholder initiative . August 2014, Andreas . Seiter. What is AIM 2030?. An initiative to maximize access to innovative medicines for priority diseases in low- and middle income countries (LMICs). how . the pandemic has influenced the disease burden. Bengt . Jönsson. Professor emeritus, Stockholm School of Economics. Wednesday, 1 July 2020 – 16.30-19.00 CET (online event. ). Launch of the European Parliament  . PI: Deanne Rogers / SUNY Stony Brook University . http://cpex.labs.stonybrook.edu/drogers/. Planetary . Science Legacy . Facilities . Description of Facility. The CEC is a glove box equipped with a relative humidity and temperature control system that permits experiments, spectral measurements and XRD measurements of RH/T-sensitive samples. Controlled Temperature Range: -25°C to Ambient .